We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Paladin Labs Announces the Canadian Launch of DigiFab™ Digoxin Immune Fab (Ovine)

Product News  
Published: December 13, 2011 
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

By submitting your email address, you agree to receive email communications related to Technology Networks content, products, or our partners. You may unsubscribe from these communications at any time as we respect your privacy. View our Privacy Policy for more information.
Read time: Less than a minute

Paladin Labs Inc. has announced the Canadian launch of DigiFab™ Digoxin Immune Fab (Ovine).

DigiFab™ is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose.

There are approximately 1.6 million digoxin prescriptions written annually in Canada.

Digoxin is known to have a narrow therapeutic window and patients can easily move from a therapeutic to toxic dose through excessive dosing, slow elimination and metabolism or through interactions with other drugs.

Digoxin toxicity can cause potentially life-threatening heart rhythm disturbances.

Paladin acquired the exclusive Canadian rights to market and sell DigiFab™ from BTG International Inc., in February 2010.

Related Topic Pages
The Immune System
Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter